Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
tipiracil
trifluridine |
| gptkbp:administeredWithFood |
yes
|
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
L01BC59
|
| gptkbp:chemicalFormula |
C10H11Cl2F3N2O5 (trifluridine)
C9H11N3O2 (tipiracil) |
| gptkbp:EMAApprovalDate |
2016
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lonsurf
|
| gptkbp:indication |
patients previously treated with anti-VEGF biological therapy
patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy patients previously treated with anti-EGFR therapy (if RAS wild-type) |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:mechanismOfAction |
nucleoside metabolic inhibitor
thymidine phosphorylase inhibitor |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue neutropenia |
| gptkbp:tradeNameOf |
trifluridine/tipiracil
|
| gptkbp:usedFor |
metastatic colorectal cancer
metastatic gastric cancer |
| gptkbp:bfsParent |
gptkb:Taiho_Pharmaceutical
gptkb:Taiho_Pharmaceutical_Co.,_Ltd. gptkb:Servier_Pharmaceuticals |
| gptkbp:bfsLayer |
7
|